Hitoshi Ban

This inventor holds 41 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Vaccine Adjuvants. Top assignees: Sumitomo Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.. Active years: 2002-2026.

USPTO Granted Patents = 41 (Patent Applications = 9)

% Patents Active = 87.8

CIPO Patents = 2 (Patent Applications = 15)

EPO Patents = 6 (Patent Applications = 20)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 68(Granted Patents)

Location History:

Nishinomiya, JP (2002 - 2022)
Hyogo, JP (2022)
Osaka, JP (2015 - 2024)

Company Filing History:

17 out of 66

Sumitomo Pharma Co., Ltd.

patents

16 out of 110

Sumitomo Dainippon Pharma Co., Ltd.

patents

4 out of 61

International Institute of Cancer Immunology, Inc.

patents

4. 4 out of 14

Sumitomo Pharma Co., Ltd.

patents

5. 2 out of 19

Boston Biomedical, Inc.

patents

6. 2 out of 11

Sumitomo Dainippon Pharma Oncology, Inc.

patents

7. 2 out of 174

Sumitomo Pharmaceuticals Company Limited

patents

8. 1 out of 11

Sumitomo Pharma Oncology, Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Vaccine Adjuvants

Substituted Pyrimidines

Hemiasterlin Derivatives

Optically Active Derivatives

Antibody-Drug Conjugates

Dihydrochromene Derivatives

Protein Kinase Inhibitors

Imidazole Derivatives

Water-Soluble Prodrugs

Naphthyridine Derivatives

AZA Bicyclic Compounds

Cancer Treatment

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673941 - TERTIARY AMIDE DERIVATIVES SUBSTITUTED WITH 4-MEMBERED RING STRUCTURE (2026-07-07),

2. 12662494 - Optically active bridged piperidine derivative (2026-06-23),

3. 12617779 - Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same (2026-05-05),

4. 12559487 - Crosslinked optically active secondary amine derivative (2026-02-24),

5. 12440560 - Substituted pyrimidines as vaccine adjuvants (2025-10-14),

6. 12427192 - Water soluble adjuvant and composition containing same (2025-09-30),

7. 12410154 - 5-heteroaryl-1H-pyrazol-3-amine derivative (2025-09-09),

8. 12398149 - Dihydrochromene derivatives (2025-08-26),

9. 12383608 - WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides (2025-08-12),

10. 12263167 - Optically active azabicyclo ring derivative (2025-04-01),

11. 12178879 - Hemiasterlin derivative and antibody-drug conjugate thereof (2024-12-31),

12. 12018093 - Hemiasterlin derivatives and antibody-drug conjugates including same (2024-06-25),

13. 11911466 - Substituted pyrimidines as vaccine adjuvants (2024-02-27),

14. 11911381 - Optically active azabicyclo ring derivative (2024-02-27),

15. 11795195 - Antibody-drug conjugates including hemiasterlin derivative (2023-10-24),

Title: Inventor Hitoshi Ban - Revolutionizing Technology in Osaka

Introduction: Hitoshi Ban is a visionary inventor based in Osaka, Japan, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Hitoshi Ban holds several patents in the areas of robotics, artificial intelligence, and renewable energy technologies, showcasing his commitment to pushing the boundaries of what is possible in the modern world.

Career Highlights: With a career spanning over two decades, Hitoshi Ban has worked with leading research institutions and tech companies to develop cutting-edge solutions that have revolutionized industries and improved the lives of many.

Collaborations: Throughout his career, Hitoshi Ban has collaborated with top engineers, scientists, and designers from around the globe, fostering a culture of innovation and creativity that has led to numerous successful projects and inventions.

Conclusion: Hitoshi Ban's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology in Osaka and beyond.